Selective BTK Kinase Inhibitors for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for primary CNS lymphoma (PCNSL) are inadequate, particularly for relapsed/refractory cases, with limited efficacy and safety concerns, and there is a need for compounds that can modulate protein kinases, especially BTK, to effectively cross the blood-brain barrier for targeted therapy.
Innovation Solution
Development of novel kinase inhibitors, specifically BTK inhibitors, represented by compounds of Formula (I), (II), and (III), with improved brain penetration and kinase selectivity, formulated into pharmaceutical compositions for targeted treatment of conditions associated with BTK activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing BTK inhibitors are used to treat PCNSL, then BTK activity is inhibited, but the compounds fail to effectively cross the blood-brain barrier
Solution Approach 1:
The patent modifies molecular parameters of BTK inhibitors by introducing specific fluorine atoms and altering the chemical structure at positions R1-R6 to enhance lipophilicity and molecular size characteristics, enabling effective penetration across the blood-brain barrier while maintaining BTK inhibition activity
Solution Approach 2:
The invention creates composite molecular structures combining established BTK inhibitor pharmacophores with novel fluorinated aromatic rings and specific side chains (Formula I, II, III compounds), achieving both blood-brain barrier penetration and effective BTK inhibition
2Reliability
If current PCNSL treatments are administered, then some therapeutic effect is achieved, but efficacy is limited and safety concerns arise
Solution Approach 1:
The patent introduces local fluorine substitutions at specific positions (R1-R6) in the molecular structure to locally enhance properties such as binding affinity to BTK and blood-brain barrier penetration, while maintaining overall safety profile through controlled structural modifications
Solution Approach 2:
The invention employs partial fluorination patterns and controlled molecular weight increases to achieve sufficient blood-brain barrier penetration without excessive off-target effects, balancing efficacy enhancement with safety maintenance
Data Source
AI summary
Disclosed herein are 1H-indole-7-carboxamide derivatives as protein kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of such protein kinase inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function. In particular, the present invention relates to selective BTK inhibitors.